Beta Drugs Limited (BETA) reported revenue of ₹126 Cr and net profit of ₹16.49 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
BETA fundamentals, Fundamental score 85/100
The statements below are read from Beta Drugs Limited’s filed results, 6 filed quarters and 9 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Jul 31, 2026 · audited
Sales CAGR · 3Y+19.2%FY22 → FY25
Sales CAGR · 4Y+20.3%FY21 → FY25
PAT CAGR · 3Y+10.2%FY22 → FY25
PAT CAGR · 4Y+13.5%FY21 → FY25
Price · 1Y+17.7%EOD
Price CAGR · 3Y+32.8%EOD
Quarterly resultsConsolidated
₹ Cr
Dec2024
Mar2025
Sep2025
Dec2025
Mar2026
Jun2026Latest
YoYlatest
Sales
88.0
182
204
87.3
94.0
126
—
70.0
146
163
70.3
76.3
98.2
—
Operating profit
18.0
35.8
41.0
17.0
17.7
27.4
—
OPM %
20.5%
19.7%
20.1%
19.5%
18.8%
21.8%
—
Other income
-1.00
4.93
5.98
2.31
2.89
1.58
—
Interest
2.00
5.16
6.93
4.43
3.94
2.56
—
Depreciation
3.00
6.80
7.97
4.39
4.80
4.35
—
Profit before tax
12.0
24.2
32.1
10.5
11.8
22.0
—
Tax %
25.0%
25.7%
25.5%
18.7%
23.5%
25.2%
—
Net profit
9.00
18.0
23.9
8.52
9.05
16.5
—
EPS (₹)
8.86
17.81
47.38
8.40
8.93
14.78
—
One column per filed quarter · ₹ crore · YoY = latest vs the same quarter a year back · EPS restated for bonus/split↔ scroll for earlier quarters
Revenue & net profit trend
last 6 quarters
RevenueNet profit
Revenue & net profit — Consolidated6 quarters
Segment results
Needs segment dataSegment results not parsedPer-segment revenue, EBIT margin and YoY arrive once we parse the segment annexure from the filing.
Forensic checksauto-scanned from the filing
Coming soonForensic checks not connectedAuditor opinion, OCF÷PAT, contingent liabilities, related-party share and working-capital days arrive as we parse the notes-to-accounts + cash-flow statement. Promoter-pledge is already on the Holdings tab.
How results moved the priceEOD reaction on the session the market could trade the filing
Avg absolute result-day move ±9.1%· EPS surprise: no estimates source· 1 earlier quarter has no dated filing on record
